Home » Stock Quotes » EBR:ARGX

argenx SE

EBR:ARGX Share Price & Live Data

Price:
118.80 EUR
Change:
-1.20 (-1.00%)
Price open 118.50
Previous close 120.00
Market cap 5.08B
Volume 73.86K
Day high 122.10
Day low 115.20
Year high 154.00
Year low 93.05

About argenx SE

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include Efgartigimod (ARGX-113) that completed Phase II clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy; and Cusatuzumab (ARGX-110), which is in Phase I/II clinical trials for the treatment of acute myeloid leukemia and T-cell lymphoma. It is also developing ARGX-117 for the treatment of severe autoimmune diseases; ARGX-111 to treat solid tumors; ARGX-112 to treat dermatologic indications; ARGX-115, a cancer immunotherapy-focused product candidate against the glycoprotein A repetitions predominant; ARGX-116 for the treatment of dyslipidemia; and ARGX-109 for the treatment of rheumatoid arthritis. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Cilag GmbH International; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Overview
Name argenx SE
Exchange Brussels Stock Exchange
Sector Healthcare
Industry Biotechnology
Country Netherlands

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.